Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy.
- Registry ID
- EUCTR2009-014409-15
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- AIBILI - Association for Innovation and Biomedical Research on Light and Image
- Start date
- 2009-10-29
- Last update
- 2026-08-16
Conditions
- Proliferative Diabetic Retinopathy.
Summary
The purpose of this trial is to evaluate safety and to compare the efficacy of intravitreous injection of ranibizumab alone (0.5 mg), versus combination of intravitreous injection of ranibizumab (0.5 mg) plus PRP, versus PRP alone in the regression of retinal neovascularization in eyes with high-risk PDR.
Locations
View on source registry